Diarrhea Trials in Chicago, United States
Conditions / Diarrhea / Chicago, United States
Research into Diarrhea spans multiple therapeutic approaches and trial phases.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00002252 | A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea | COMPLETED | NA |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | COMPLETED | PHASE3 |
| NCT00003825 | Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy | COMPLETED | PHASE3 |
| NCT00093353 | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | COMPLETED | — |
| NCT00003057 | Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer | COMPLETED | PHASE3 |
| NCT00269399 | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | COMPLETED | PHASE3 |
| NCT00048971 | Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy | COMPLETED | — |
| NCT00468728 | PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | COMPLETED | PHASE3 |
| NCT00002253 | A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either Responders or Non-Responders in a Prior Placebo-Controlled Double-Blind Sandostatin Study. | COMPLETED | NA |
| NCT01198145 | Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy | COMPLETED | PHASE3 |